Stay updated on Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.

Latest updates to the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.6.4 is now shown on the page, replacing Revision: v3.6.3, indicating an updated version of the page. This change appears to be a metadata/version update rather than a substantive alteration to study data or content.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page’s revision label was updated from v3.6.2 to v3.6.3. This reflects a minor refresh of the page template or content rendering.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a newer build of the page. This change updates the page version without altering the displayed study details.SummaryDifference0.1%

- Check56 days agoChange DetectedRecruitment status changed to closed with added guidance sections for joining and reading the study, and the Intervention/Treatment heading and revision label were updated to reflect the latest structure (v3.6.0).SummaryDifference0.5%

- Check63 days agoChange DetectedRevision tag updated from v3.5.4 to v3.5.5 on the page, indicating a minor internal update to the study record. This change reflects version control rather than content changes to the study details.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page shows a revision tag updated from v3.5.3 to v3.5.4, representing an internal site version update rather than a change to the trial information.SummaryDifference0.2%

Stay in the know with updates to Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.